Is anyone else a little worried that they may be attempting to diversify too much? I often find with these types of companies that it is best to focus on one core product with the greatest potential. Yes, the greater diversification takes some risk off the table but is this really necessary now with the significant and likely potential of hepafat following the FDA approval? The way I see it considering the size of this market the best value can be delivered to shareholders through focusing on the marketing of hepafat while we have a first mover advantage. After we have developed a solid reputation then diversification should be considered but I feel they may be putting far too much on the plate all at once. Of course, I am still doing my own research so please let me know if am missing something here. Cheers
- Forums
- ASX - By Stock
- RHT
- Ann: R&D Update - Molecular Medicine ASO Project
Ann: R&D Update - Molecular Medicine ASO Project, page-9
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RHT (ASX) to my watchlist
|
|||||
Last
6.0¢ |
Change
0.002(3.45%) |
Mkt cap ! $26.81M |
Open | High | Low | Value | Volume |
5.8¢ | 6.0¢ | 5.8¢ | $11.96K | 203.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 315821 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 3100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 315821 | 0.059 |
2 | 165000 | 0.055 |
1 | 75000 | 0.054 |
1 | 19229 | 0.052 |
1 | 200000 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.062 | 3100 | 1 |
0.063 | 43798 | 1 |
0.065 | 75000 | 1 |
0.066 | 140246 | 1 |
0.068 | 236190 | 2 |
Last trade - 13.03pm 11/09/2024 (20 minute delay) ? |
Featured News
RHT (ASX) Chart |